NCT04202835: ATG Plus PTCy vs ATG for CGVHD Prophylaxis
- State
- Under way
- Phase
- Phase 2
- People
- 80 planned
- Started
- 14 Oct 2020
- Primary completion
- 18 May 2024
- Arms
- ATG/PTCy
- Results
- None posted
- 18 Dec 2019: Trial registered
- 14 Oct 2020: Trial started
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Kind of treatment: Drug.
Also known as ARM A Cyclophosphamide, Cycloblastin, Cyclostin, Cytophosphan, Cytoxan, Cyclophosphamide 250 mg/m2; 3 days, Cyclophosphamide 35mg/kg/day, Cyclophosphamide 500 mg/m2; 2 doses, Cyclophosphamide 500 mg/m2; 3 doses, Cyclophosphamide 900 mg/m2; 1 day, Endoxan, Neosar, Procytox, Revimmune.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.